Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347292 · ClinicalTrials.gov registry record · Phase 1
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT03347292 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 58 participants.
The verdict
NCT03347292, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, status or response. The study will also investigate how the drugs behave in your body
Interventions
- DRUG Pembrolizumab
- DRUG Regorafenib(Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347292
The ClinicalTrials.gov registry entry for NCT03347292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03347292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03347292 about?
NCT03347292 is a clinical study titled "Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC". This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with d...
What is the current status of trial NCT03347292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2018-06-18. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT03347292?
The interventions under investigation include: Pembrolizumab (DRUG), Regorafenib(Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT03347292?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.